Everest Medicines Acquires Exclusive Rights to VIS-101 for Serious Eye Disorders
Everest Medicines has acquired an exclusive license to develop, manufacture, and commercialize VIS-101, a novel bifunctional biologic, in Greater China, Singapore, South Korea, and certain Southeast Asian countries.
The collaboration is with Visara, Inc., a subsidiary of NovaBridge Biosciences, and marks Everest's expansion into ophthalmology, a high-potential therapeutic area.
- Upfront payment: US$7 million (approximately RMB49.7 million)
- Reimbursement for prior expenses: up to RMB24.0 million
- Potential future payments: up to US$89 million
This collaboration further enriches Everest's late-stage product pipeline and strengthens synergies across its core therapeutic portfolio.
Author's summary: Everest Medicines expands into ophthalmology with VIS-101 license.